Stockreport

Immatics Announces Full Year 2025 Financial Results and Business Update [Yahoo! Finance]

Immatics N.V. - Ordinary Shares  (IMTX) 
PDF previously treated advanced melanoma ongoing; anzu-cel received Orphan Drug Designation from the FDA for the treatment of both cutaneous and uveal melanoma SUPRAME tim [Read more]